MONTE ROSA THERAPEUTICS INC (GLUE)
US61225M1027 - Common Stock
ChartMill assigns a Buy % Consensus number of 86% to GLUE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 16.76. This target is 135.35% above the current price.
GLUE was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about GLUE.
In the previous month the buy percentage consensus was at a similar level.
GLUE was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-19 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-09-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-06-28 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-05-22 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-02-15 | Wedbush | Initiate | Outperform |
| 2023-10-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-08-11 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-05-12 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-03-17 | Credit Suisse | Maintains | Neutral |
| 2023-01-03 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2022-10-13 | UBS | Initiate | Buy |
| 2022-08-15 | Jefferies | Initiate | Buy |
| 2022-05-12 | Piper Sandler | Maintains | Overweight |
| 2022-04-28 | Credit Suisse | Initiate | Neutral |
| 2022-02-10 | Wells Fargo | Initiate | Equal-Weight |
| 2021-10-14 | SVB Leerink | Initiate | Market Perform |
| 2021-07-19 | Guggenheim | Initiate | Buy |
| 2021-07-19 | JP Morgan | Initiate | Overweight |
| 2021-07-19 | Piper Sandler | Initiate | Overweight |